Research has confirmed substantial differences between HER2-low and HER2-zero breast cancers regarding Ki-67 expression levels, hormone receptor status, and mutation rates in the PI3K-Akt signaling pathway (8), disease-free survival, overall survival (44), and response to neoadjuvant chemotherapy (7). Here, ERBB2 is linked to breast carcinoma.